Business
Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
Focus on SER-287 and SER-301, Seres’ microbiome therapeutic candidates in development for ulcerative colitis Event to be held ahead of Phase 2b ECO-RESET
About this update from Seres Therapeutics, Inc.
[{"type":"text","content":"\nFocus on SER-287 and SER-301, Seres’ microbiome therapeutic candidates in development for ulcerative colitis\n\nEvent to be held ahead of Phase 2b ECO-RESET study clinical induction results anticipated in mid-2021, with additional microbiome pharmacology data expected in H2 2021\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSeres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will host a virtual investor event focused on SER-287 and SER-301, potential new therapeutic options for ulcerative colitis (UC) on Monday, June 21, 2021 from 8:30 a.m. to 10:00 a.m. ET.\n\nDuring the event, Seres’ management and Stephen Hanauer, M.D., Professor of Medicine at Northwestern University Feinberg School of Medicine will discuss the UC patient burden, the need for new therapeutic approaches, and SER-287 and SER-301, Seres’ microbiome therapeutic candidates in clinical development for UC.\n\nSeres is conducting a Phase 2b trial of SER-287 in individuals with active mild-to-moderate UC. SER-287 is an oral microbiome therapeutic candidate designed to restructure the gastrointestinal microbiome and reduce inflammation. Topline clinical data from the SER-287 Phase 2b induction study are expected in mid-2021 and additional microbiome pharmacology data are expected in H2 2021. Seres is also evaluating SER-301, a cultivated rationally designed microbiome therapeutic candidate, in a Phase 1b study in individuals with active mild-to-moderate UC.\n\nTo join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com. To access the event via conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 5387033.\n\nA webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.\n\nAbout Seres Therapeutics\n\nSeres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SE...